NCI Outstanding Investigator Award (R35 Clinical Trial Optional)
Funding Agency:
- National Institutes of Health
The purpose of the National Cancer Institute (NCI) Outstanding Investigator Award is to provide long-term support and increased flexibility for investigators with outstanding records of research accomplishments to continue or to embark upon a research program of unusual potential in cancer. Candidates for the OIA must be nominated by their applicant organization which should consider nominating meritorious mid-career, women and under represented minority candidates. Special features of the OIA include 7-year project periods; the expectation that the OIA PD/PI commit at least 6 person months effort to the OIA; the expectation of clear and substantial Institutional commitment to the PD/PI, for example, providing 20% of salary support; and that PD/PIs will be expected to renegotiate their time and effort on all other grant support, including NIH grants, in order to accommodate the OIA level of effort. It is expected that the OIA will replace current NCI funding on individual research grants. If an OIA is awarded, the NCI will only consider funding two additional research project grants to the Outstanding Investigator while the OIA is active. This limit includes single PD/PI, multiple PD/PI and multi-project grants where the OIA Investigator is the PD/PI. The NCI will not approve a change of PD/PI on an existing NCI grant to avoid the OIA requirements. An OIA investigator who was awarded two additional NCI grants (as PD/PI) in the last OIA project period will not be awarded another NCI grant, in addition to the OIA (R35), while those grants remain active.
Awards will be for $600,000 direct costs per year, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award.
November 08, 2022
Christine Siemon, National Cancer Institute (NCI), Telephone: 240-276-6266,, Email:siemonc@nih.gov